|
Activity Number:
|
355
- Contributed Poster Presentations: Biopharmaceutical Section
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Tuesday, July 30, 2019 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
|
Abstract #304955
|
|
|
Title:
|
Nonparametric Bayesian Method for Drug Combination with Discrete Doses
|
|
Author(s):
|
Zahra Razaee* and Galen Cook-Wiens and Mourad Tighiouart
|
|
Companies:
|
Cedars-Sinai Medical Center and Cedars Sinai Medical Center and Cedars-Sinai Medical Center
|
|
Keywords:
|
Cancer Phase I Trials;
Maximum tolerated dose;
drug combination;
dose limiting toxicity;
partial ordering
|
|
Abstract:
|
We propose an adaptive design for early-phase drug-combination cancer trials with the goal of estimating the maximum tolerated dose (MTD). A nonparametric Bayesian model, using Beta priors truncated to the set of partially ordered dose combinations, is used to describe the probability of dose limiting toxicity (DLT). Dose allocation between successive cohorts of patients is estimated using a modified Continual Reassessment scheme. The updated probabilities of DLT are calculated with a Gibbs sampler that employs a weighting mechanism to calibrate the influence of data versus the prior. At the end of the trial, we recommend one or more dose combinations as the MTD based on our proposed algorithm. The design operating characteristics indicate that our method is comparable with existing methods.
|
Authors who are presenting talks have a * after their name.
